44.52
+0.2335(+0.53%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
316
First IPO Date
November 05, 2014
| Name | Title | Pay | Year Born |
| Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. | President, Chief Executive Officer, Principal Accounting Officer & Director | 1.18M | 1976 |
| Dr. James R. Empfield Ph.D. | Executive Vice President of Drug Discovery | 323,428 | 1961 |
| Dr. Robin P. Sherrington Ph.D. | Executive Vice President of Strategy & Innovation | 587,028 | 1961 |
| Ms. Andrea DiFabio J.D. | Chief Legal Officer & Corporate Secretary | 682,252 | 1968 |
| Dr. Christopher John Kenney M.D. | Chief Medical Officer | 774,702 | 1971 |
| Dr. Matthew D. Ronsheim Ph.D. | Chief Operating Officer | 0 | 1972 |
| Ms. Shelley McClCoskey B.A. | Executive Vice President of Human Resources | 0 | 1960 |
| Mr. Darren S. Cline M.B.A. | Chief Commercial Officer and Member of Executive Team | 0 | 1964 |
| Mr. Thomas Patrick Kelly J.D. | Chief Financial Officer | 0 | 1971 |
| Ms. Colleen Alabiso | Senior Vice President of Corporate Affairs | 0 | N/A |
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.